Herbal and alternative approaches to obesity

Handbook of Obesity: Clinical Applications, Third Edition

Volumn , Issue , 2008, Pages 425-452

  Greenway, Frank ^a   Heber, David ^b  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954616306     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (271)

1. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. New Engl J Med 2000; 343:1833-1838.
2. Final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk. Final rule. Fed Regist 2004; 69:6787-6854.
3. Inchiosa M. Letter to the Editor. Concerning ephedra alkaloids for weight loss. Int J Obes 2007; 31(9):1481.
4. Malchow-Moller A, Larsen S, Hey H, et al. Ephedrine as an anorectic: the story of the ‘Elsinore pill’. Int J Obes 1981; 5:183-187.
5. Goodman L. The Pharmacological Basis of Therapeutics. 7th ed. New York: Macmillan Publishing Company, 1985.
6. Drug Topics Red Book. Montvale, NJ: Medical Economics Company, Inc., 2000.
7. Astrup A, Breum L, Toubro S, et al. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energyrestricted diet. A double blind trial. Int J Obes Relat Metab Disord 1992; 16:269-277.
8. Toubro S, Astrup A, Breum L, et al. The acute and chronic effects of ephedrine/caffeine mixtures on energy expenditure and glucose metabolism in humans. Int J Obes Relat Metab Disord 1993; 17(suppl 3):S73-S77.
9. Astrup A, Toubro S, Christensen NJ, Quaade F. Pharmacology of thermogenic drugs. Am J Clin Nutr 1992; 55:246S-248S.
10. Astrup A, Toubro S. Thermogenic, metabolic, and cardiovascular responses to ephedrine and caffeine in man. Int J Obes Relat Metab Disord 1993; 17(suppl 1):S41-S43.
11. Astrup A, Buemann B, Christensen NJ, et al. The effect of ephedrine/caffeine mixture on energy expenditure and body composition in obese women. Metabolism 1992; 41:686-688.
12. Buemann B, Marckmann P, Christensen NJ, et al. The effect of ephedrine plus caffeine on plasma lipids and lipoproteins during a 4.2 MJ/day diet. Int J Obes Relat Metab Disord 1994; 18:329-332.
13. Molnar D. Effects of ephedrine and aminophylline on resting energy expenditure in obese adolescents. Int J Obes Relat Metab Disord 1993; 17(suppl 1):S49-S52.
14. Molnar D, Torok K, Erhardt E, et al. Safety and efficacy of treatment with an ephedrine/caffeine mixture. The first double-blind placebo-controlled pilot study in adolescents. Int J Obes Relat Metab Disord 2000; 24:1573-1578.
15. Vansal SS, Feller DR. Direct effects of ephedrine isomers on human beta-adrenergic receptor subtypes. Biochem Pharmacol 1999; 58:807-810.
16. Greenway FL, Raum WJ, DeLany JP. The effect of an herbal dietary supplement containing ephedrine and caffeine on oxygen consumption in humans. J Altern Complement Med 2000; 6:553-555.
17. Greenway FL, de Jonge L, Blanchard D, et al. Effect of a dietary herbal supplement containing caffeine and ephedra on weight, metabolic rate, and body composition. Obes Res 2004; 12:1152-1157.
18. Gwirtsman H, Virts K, Chen K, et al. An ephedrine, caffeine, and chromium compound acutely increases energy expenditure in healthy obese adults: a placebocontrolled, crossover study. Obes Res 1999; 7:117S.
19. Boozer CN, Daly PA, Homel P, et al. Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial. Int J Obes Relat Metab Disord 2002; 26:593-604.
20. Shekelle PG, Hardy ML, Morton SC, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA 2003; 289:1537-1545.
21. Dietary Supplement Market View. Washington D.C., 2000.
22. Moore N, Noblet C, Breemeersch C. Focus on the safety of ibuprofen at the analgesic-antipyretic dose. Therapie 1996; 51:458-463.
23. Steele VE, Kelloff GJ, Balentine D, et al. Comparative chemopreventive mechanisms of green tea, black tea and selected polyphenol extracts measured by in vitro bioassays. Carcinogenesis 2000; 21:63-67.
24. Sesso HD, Gaziano JM, Buring JE, et al. Coffee and tea intake and the risk of myocardial infarction. Am J Epidemiol 1999; 149:162-167.
25. Dulloo A, Seydoux J, Giradier L. Tealine and thermogenesis:interactions between polyphenols, caffeine and sympathetic activity. Int J Obes 1996; 20:71.
26. Dulloo AG, Duret C, Rohrer D, et al. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. Am J Clin Nutr 1999; 70:1040-1045.
27. Chantre P, Lairon D. Recent findings of green tea extract AR25 (Exolise) and its activity for the treatment of obesity. Phytomedicine 2002; 9:3-8.
28. Westerterp-Plantenga MS, Lejeune MP, Kovacs EM. Body weight loss and weight maintenance in relation to habitual caffeine intake and green tea supplementation. Obes Res 2005; 13:1195-1204.
29. Gougeon R, Harrigan K, Tremblay JF, et al. Increase in the thermic effect of food in women by adrenergic amines extracted from citrus aurantium. Obes Res 2005; 13:1187-1194.
30. Colker C, Kalman D, Torina G, et al. Effects of citrus aurantium extract, caffeine and St. John’s wort on body fat loss, lipid levels and mood state in overweight healthy adults. Curr Ther Res 1999; 60:145-153.
31. Greenway F, de Jonge-Levitan L, Martin C, et al. Dietary herbal supplements with phenylephrine for weight loss. J Med Food 2006; 9:572-578.
32. Nasir JM, Durning SJ, Ferguson M, et al. Exerciseinduced syncope associated with QT prolongation and ephedra-free Xenadrine. Mayo Clin Proc 2004; 79:1059-1062.
33. Min B, Cios D, Kluger J, et al. Absence of QTc-intervalprolonging or hemodynamic effects of a single dose of bitter-orange extract in healthy subjects. Pharmacotherapy 2005; 25:1719-1724.
34. Nykamp DL, Fackih MN, Compton AL. Possible association of acute lateral-wall myocardial infarction and bitter orange supplement. Ann Pharmacother 2004; 38:812-816.
35. Zhang LL, Yan Liu D, Ma LQ, et al. Activation of transient receptor potential vanilloid type-1 channel prevents adipogenesis and obesity. Circ Res 2007; 100:1063-1070.
36. Hwang JT, Park IJ, Shin JI, et al. Genistein, EGCG, and capsaicin inhibit adipocyte differentiation process via activating AMP-activated protein kinase. Biochem Biophys Res Commun 2005; 338:694-699.
37. Hsu CL, Yen GC. Effects of capsaicin on induction of apoptosis and inhibition of adipogenesis in 3T3-L1 cells. J Agric Food Chem 2007; 55:1730-1736.
38. Doucet E, Tremblay A. Food intake, energy balance and body weight control. Eur J Clin Nutr 1997; 51:846-855.
39. Matsumoto T, Miyawaki C, Ue H, et al. Effects of capsaicin-containing yellow curry sauce on sympathetic nervous system activity and diet-induced thermogenesis in lean and obese young women. J Nutr Sci Vitaminol (Tokyo) 2000; 46:309-315.
40. Westerterp-Plantenga MS, Smeets A, Lejeune MP. Sensory and gastrointestinal satiety effects of capsaicin on food intake. Int J Obes (Lond) 2005; 29:682-688.
41. Tsi D, Nah AK, Kiso Y, et al. Clinical study on the combined effect of capsaicin, green tea extract and essence of chicken on body fat content in human subjects. J Nutr Sci Vitaminol (Tokyo) 2003; 49:437-441.
42. Belza A, Frandsen E, Kondrup J. Body fat loss achieved by stimulation of thermogenesis by a combination of bioactive food ingredients: a placebo-controlled, doubleblind 8-week intervention in obese subjects. Int J Obes (Lond) 2007; 31:121-130.
43. Masuda Y, Haramizu S, Oki K, et al. Upregulation of uncoupling proteins by oral administration of capsiate, a nonpungent capsaicin analog. J Appl Physiol 2003; 95:2408-2415.
44. Kobayashi Y, Nakano Y, Kizaki M, et al. Capsaicin-like anti-obese activities of evodiamine from fruits of Evodia rutaecarpa, a vanilloid receptor agonist. Planta Med 2001; 67:628-633.
45. Morimoto C, Satoh Y, Hara M, et al. Anti-obese action of raspberry ketone. Life Sci 2005; 77:194-204.
46. Inuoe N, Matsunaga Y, Satoh H, et al. Enhancement of energy expenditure and fat oxidation in human subjects by ingestion of novel and nonpungent capsaicin analogues (capsinoids). Obesity 2006; 14:A67.
47. Maeda H, Hosokawa M, Sashima T, et al. Fucoxanthin from edible seaweed, Undaria pinnatifida, shows antiobesity effect through UCP1 expression in white adipose tissues. Biochem Biophys Res Commun 2005; 332:392-397.
48. Maeda H, Hosokawa M, Sashima T, Takahashi N, Kawada T, Miyashita K. Fucoxanthin and its metabolite, fucoxanthinol, suppress adipocyte differentiation in 3T3-L1 cells. Int J Mol Med 2006; 18:147-152.
49. Liao HF, Tsai WC, Chang SW, et al. Application of solvent engineering to optimize lipase-catalyzed 1,3-diglyacylcerols by mixture response surface methodology. Biotechnol Lett 2003; 25:1857-1861.
50. Rudkowska I, Roynette CE, Demonty I, et al. Diacylglycerol:efficacy and mechanism of action of an anti-obesity agent. Obes Res 2005; 13:1864-1876.
51. Taguchi H, Nagao T, Watanabe H, et al. Energy value and digestibility of dietary oil containing mainly 1,3-diacylglycerol are similar to those of triacylglycerol. Lipids 2001; 36:379-382.
52. Kamphuis MM, Mela DJ, Westerterp-Plantenga MS. Diacylglycerols affect substrate oxidation and appetite in humans. Am J Clin Nutr 2003; 77:1133-1139.
53. Nagao T, Watanabe H, Goto N, et al. Dietary diacylglycerol suppresses accumulation of body fat compared to triacylglycerol in men in a double-blind controlled trial. J Nutr 2000; 130:792-797.
54. Maki KC, Davidson MH, Tsushima R, et al. Consumption of diacylglycerol oil as part of a reduced-energy diet enhances loss of body weight and fat in comparison with consumption of a triacylglycerol control oil. Am J Clin Nutr 2002; 76:1230-1236.
55. Matsuyama T, Shoji K, Watanabe H, et al. Effects of diacylglycerol oil on adiposity in obese children: initial communication. J Pediatr Endocrinol Metab 2006; 19:795-804.
56. Yasunaga K, Glinsmann WH, Seo Y, et al. Safety aspects regarding the consumption of high-dose dietary diacylglycerol oil in men and women in a double-blind controlled trial in comparison with consumption of a triacylglycerol control oil. Food Chem Toxicol 2004; 42:1419-1429.
57. Taguchi H, Watanabe H, Onizawa K, et al. Double-blind controlled study on the effects of dietary diacylglycerol on postprandial serum and chylomicron triacylglycerol responses in healthy humans. J Am Coll Nutr 2000; 19:789-796.
58. Ai M, Tanaka A, Shoji K, et al. Suppressive effects of diacylglycerol oil on postprandial hyperlipidemia in insulin resistance and glucose intolerance. Atherosclerosis 2006; 195(2):398-403.
59. Yamamoto K, Asakawa H, Tokunaga K, et al. Effects of diacylglycerol administration on serum triacylglycerol in a patient homozygous for complete lipoprotein lipase deletion. Metabolism 2005; 54:67-71.
60. Yamamoto K, Asakawa H, Tokunaga K, et al. Long-term ingestion of dietary diacylglycerol lowers serum triacylglycerol in type II diabetic patients with hypertriglyceridemia. J Nutr 2001; 131:3204-3207.
61. Yamamoto K, Tomonobu K, Asakawa H, et al. Diet therapy with diacylglycerol oil delays the progression of renal failure in type 2 diabetic patients with nephropathy. Diabetes Care 2006; 29:417-419.
62. Kim YJ, Shin YO, Ha YW, et al. Anti-obesity effect of Pinellia ternata extract in Zucker rats. Biol Pharm Bull 2006; 29:1278-1281.
63. Choi Y, Kim YC, Han YB, et al. The trans-10, cis-12 isomer of conjugated linoleic acid downregulates stearoyl-CoA desaturase 1 gene expression in 3T3-L1 adipocytes. J Nutr 2000; 130:1920-1924.
64. Griinari JM, Corl BA, Lacy SH, et al. Conjugated linoleic acid is synthesized endogenously in lactating dairy cows by Delta(9)-desaturase. J Nutr 2000; 130:2285-2291.
65. Dhiman TR, Satter LD, Pariza MW, et al. Conjugated linoleic acid (CLA) content of milk from cows offered diets rich in linoleic and linolenic acid. J Dairy Sci 2000; 83:1016-1027.
66. Kritchevsky D. Antimutagenic and some other effects of conjugated linoleic acid. Br J Nutr 2000; 83:459-465.
67. MacDonald HB. Conjugated linoleic acid and disease prevention: a review of current knowledge. J Am Coll Nutr 2000; 19:111S-118S.
68. Pariza MW, Park Y, Cook ME. Conjugated linoleic acid and the control of cancer and obesity. Toxicol Sci 1999; 52:107-110.
69. Park Y, Storkson JM, Albright KJ, et al. Evidence that the trans-10, cis-12 isomer of conjugated linoleic acid induces body composition changes in mice. Lipids 1999; 34:235-241.
70. Park Y, Albright KJ, Liu W, et al. Effect of conjugated linoleic acid on body composition in mice. Lipids 1997; 32:853-858.
71. West DB, Delany JP, Camet PM, et al. Effects of conjugated linoleic acid on body fat and energy metabolism in the mouse. Am J Physiol 1998; 275:R667-R672.
72. DeLany JP, Blohm F, Truett AA, et al. Conjugated linoleic acid rapidly reduces body fat content in mice without affecting energy intake. Am J Physiol 1999; 276:R1172-R1179.
73. Yamasaki M, Mansho K, Mishima H, et al. Dietary effect of conjugated linoleic acid on lipid levels in white adipose tissue of Sprague-Dawley rats. Biosci Biotechnol Biochem 1999; 63:1104-1106.
74. Tsuboyama-Kasaoka N, Takahashi M, Tanemura K, et al. Conjugated linoleic acid supplementation reduces adipose tissue by apoptosis and develops lipodystrophy in mice. Diabetes 2000; 49:1534-1542.
75. Satory DL, Smith SB. Conjugated linoleic acid inhibits proliferation but stimulates lipid filling of murine 3T3-L1 preadipocytes. J Nutr 1999; 129:92-97.
76. Azain MJ, Hausman DB, Sisk MB, et al. Dietary conjugated linoleic acid reduces rat adipose tissue cell size rather than cell number. J Nutr 2000; 130:1548-1554.
77. Tricon S, Burdge GC, Williams CM, et al. The effects of conjugated linoleic acid on human health-related outcomes. Proc Nutr Soc 2005; 64:171-182.
78. Whigham LD, O’Shea M, Mohede IC, et al. Safety profile of conjugated linoleic acid in a 12-month trial in obese humans. Food Chem Toxicol 2004; 42:1701-1709.
79. Larsen TM, Toubro S, Gudmundsen O, et al. Conjugated linoleic acid supplementation for 1 y does not prevent weight or body fat regain. Am J Clin Nutr 2006; 83:606-612.
80. Gaullier JM, Halse J, Hoye K, et al. Conjugated linoleic acid supplementation for 1 y reduces body fat mass in healthy overweight humans. Am J Clin Nutr 2004; 79:1118-1125.
81. Gaullier JM, Halse J, Hoye K, et al. Supplementation with conjugated linoleic acid for 24 months is well tolerated by and reduces body fat mass in healthy, overweight humans. J Nutr 2005; 135:778-784.
82. Riserus U, Vessby B, Arnlov J, et al. Effects of cis-9, trans-11 conjugated linoleic acid supplementation on insulin sensitivity, lipid peroxidation, and proinflammatory markers in obese men. Am J Clin Nutr 2004; 80:279-283.
83. Riserus U, Arner P, Brismar K, et al. Treatment with dietary trans-10 cis-12 conjugated linoleic acid causes isomer-specific insulin resistance in obese men with the metabolic syndrome. Diabetes Care 2002; 25:1516-1521.
84. Riserus U, Vessby B, Arner P, et al. Supplementation with trans-10 cis-12-conjugated linoleic acid induces hyperproinsulinaemia in obese men: close association with impaired insulin sensitivity. Diabetologia 2004; 47:1016-1019.
85. Riserus U, Berglund L, Vessby B. Conjugated linoleic acid (CLA) reduced abdominal adipose tissue in obese middle-aged men with signs of the metabolic syndrome: a randomised controlled trial. Int J Obes Relat Metab Disord 2001; 25:1129-1135.
86. Kamphuis MM, Lejeune MP, Saris WH, et al. Effect of conjugated linoleic acid supplementation after weight loss on appetite and food intake in overweight subjects. Eur J Clin Nutr 2003; 57:1268-1274.
87. Desroches S, Chouinard PY, Galibois I, et al. Lack of effect of dietary conjugated linoleic acids naturally incorporated into butter on the lipid profile and body composition of overweight and obese men. Am J Clin Nutr 2005; 82:309-319.
88. Sullivan C, Triscari J. Metabolic regulation as a control for lipid disorders. I. Influence of (-)-hydroxycitrate on experimentally induced obesity in the rodent. Am J Clin Nutr 1977; 30:767-776.
89. Badmaev V, Majeed M. Open field, physician-controlled evaluation of botanical weight loss formula citrin. Presented at Nutracon: Nutraceuticals, Dietary Supplements and Functional Foods. Las Vegas, NV, 1995.
90. Kriketos AD, Thompson HR, Greene H, et al. (-)-Hydroxycitric acid does not affect energy expenditure and substrate oxidation in adult males in a post-absorptive state. Int J Obes Relat Metab Disord 1999; 23:867-873.
91. Heymsfield SB, Allison DB, Vasselli JR., et al. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomized controlled trial. JAMA 1998; 280:1596-1600.
92. Mattes RD, Bormann L. Effects of (-)-hydroxycitric acid on appetitive variables. Physiol Behav 2000; 71:87-94.
93. Kovacs EM, Westerterp-Plantenga MS, de Vries M, Brouns F, et al. Effects of 2-week ingestion of (-)-hydroxycitrate and (-)-hydroxycitrate combined with medium-chain triglycerides on satiety and food intake. Physiol Behav 2001; 74:543-549.
94. Downs BW, Bagchi M, Subbaraju GV, et al. Bioefficacy of a novel calcium-potassium salt of (-)-hydroxycitric acid. Mutat Res 2005; 579:149-162.
95. Preuss HG, Garis RI, Bramble JD, et al. Efficacy of a novel calcium/potassium salt of (-)-hydroxycitric acid in weight control. Int J Clin Pharmacol Res 2005; 25:133-144.
96. Roy S, Rink C, Khanna S, et al. Body weight and abdominal fat gene expression profile in response to a novel hydroxycitric acid-based dietary supplement. Gene Expr 2004; 11:251-262.
97. Saito M, Ueno M, Ogino S, et al. High dose of Garcinia cambogia is effective in suppressing fat accumulation in developing male Zucker obese rats, but highly toxic to the testis. Food Chem Toxicol 2005; 43:411-419.
98. Bhatt AD, Dalal DG, Shah SJ, et al. Conceptual and methodologic challenges of assessing the short-term efficacy of Guggulu in obesity: data emergent from a naturalistic clinical trial. J Postgrad Med 1995; 41:5-7.
99. Sidhu L, Sharma K, Puri A, et al. Effect of gum guggul on body weight and subcutaneous tissue folds. J Res Indian Med Yoga Hom 1976; 11:16-22.
100. Kotiyal P, Singh D, Bisht D. Gum guggulu (Commiphora mukul) fraction “A” in obesity: a double-blind clinical trial. J Res Ayur Siddha 1985; 6:20-35.
101. Antonio J, Colker C, Torina G, et al. Effects of a standardized guggulsterone phosphate supplement on body composition in overweight adults: a pilot study. Curr Ther Res 1999; 60:220-227.
102. Paranjpe P, Patki P, Patwardhan B. Ayurvedic treatment of obesity: a randomised double-blind, placebo-controlled clinical trial. J Ethnopharmacol 1990; 29:1-11.
103. Oben J, Kuate D, Agbor G, et al. The use of a Cissus quadrangularis formulation in the management of weight loss and metabolic syndrome. Lipids Health Dis 2006; 5:24.
104. Oben JE, Enyegue DM, Fomekong GI, et al. The effect of Cissus quadrangularis (CQR-300) and a Cissus formulation (CORE) on obesity and obesity-induced oxidative stress. Lipids Health Dis 2007; 6:4.
105. Haslett C, Douglas JG, Chalmers SR, et al. A double-blind evaluation of evening primrose oil as an antiobesity agent. Int J Obes 1983; 7:549-553.
106. MacLean DB, Luo LG. Increased ATP content/production in the hypothalamus may be a signal for energy-sensing of satiety: studies of the anorectic mechanism of a plant steroidal glycoside. Brain Res 2004; 1020:1-11.
107. Phytopharm. Hoodia Factfile. Available at: http://www .phytopharm.co.uk/hoodiafactfile/. Accessed October 1, 2007.
108. Kuriyan R, Raj T, Srinivas SK, et al. Effect of Caralluma fimbriata extract on appetite, food intake and anthropometry in adult Indian men and women. Appetite 2007; 48:338-344.
109. Stanko RT, Tietze DL, Arch JE. Body composition, energy utilization, and nitrogen metabolism with a 4.25-MJ/day low-energy diet supplemented with pyruvate. Am J Clin Nutr 1992; 56:630-635.
110. Stanko RT, Arch JE. Inhibition of regain in body weight and fat with addition of 3-carbon compounds to the diet with hyperenergetic refeeding after weight reduction. Int J Obes Relat Metab Disord 1996; 20:925-930.
111. Kalman D, Colker CM, Wilets I, et al. The effects of pyruvate supplementation on body composition in overweight individuals. Nutrition 1999; 15:337-340.
112. Koh-Banerjee PK, Ferreira MP, Greenwood M, et al. Effects of calcium pyruvate supplementation during training on body composition, exercise capacity, and metabolic responses to exercise. Nutrition 2005; 21:312-319.
113. Kucio C. Does yohimbine act as a slimming drug?. Isr J Med Sci 1991; 27, 550-556.
114. Sax L. Yohimbine does not affect fat distribution in men. Int J Obes 1991; 15:561-565.
115. Clore JN. Dehydroepiandrosterone and body fat. Obes Res 1995; 3(suppl 4):613S-616S.
116. Abrahamsson L, Hackl H. Catabolic effects and the influence on hormonal variables under treatment with Gynodian-Depot or dehydroepiandrosterone (DHEA) oenanthate. Maturitas 1981; 3:225-234.
117. Nestler JE, Barlascini CO, Clore JN, et al. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab 1988; 66:57-61.
118. Mortola JF, Yen SS. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J Clin Endocrinol Metab 1990; 71:696-704.
119. Usiskin KS, Butterworth S, Clore JN, et al. Lack of effect of dehydroepiandrosterone in obese men. Int J Obes 1990; 14:457-463.
120. Welle S, Jozefowicz R, Statt M. Failure of dehydroepiandrosterone to influence energy and protein metabolism in humans. J Clin Endocrinol Metab 1990; 71:1259-1264.
121. Morales AJ, Nolan JJ, Nelson JC, et al. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994; 78:1360-1367.
122. Morales AJ, Haubrich RH, Hwang JY, et al. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in ageadvanced men and women. Clin Endocrinol (Oxf) 1998; 49:421-432.
123. Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. JAMA 2004; 292:2243-2248.
124. Hernandez-Morante JJ, Milagro F, Gabaldon JA, et al. Effect of DHEA-sulfate on adiponectin gene expression in adipose tissue from different fat depots in morbidly obese humans. Eur J Endocrinol 2006; 155:593-600.
125. Porter DJ, Raymond LW, Anastasio GD. Chromium:friend or foe? Arch Fam Med 1999; 8:386-390.
126. Page TG, Southern LL, Ward TL, et al. Effect of chromium picolinate on growth and serum and carcass traits of growing-finishing pigs. J Anim Sci 1993; 71:656-662.
127. Mooney KW, Cromwell GL. Efficacy of chromium picolinate and chromium chloride as potential carcass modifiers in swine. J Anim Sci 1997; 75:2661-2671.
128. Mooney KW, Cromwell GL. Effects of dietary chromium picolinate supplementation on growth, carcass characteristics, and accretion rates of carcass tissues in growingfinishing swine. J Anim Sci 1995; 73:3351-3357.
129. Lindemann MD, Wood CM, Harper AF, et al. Dietary chromium picolinate additions improve gain: feed and carcass characteristics in growing-finishing pigs and increase litter size in reproducing sows. J Anim Sci 1995; 73:457-465.
130. Boleman SL, Boleman SJ, Bidner TD, et al. Effect of chromium picolinate on growth, body composition, and tissue accretion in pigs. J Anim Sci 1995; 73:2033-2042.
131. Myers MJ, Farrell DE, Evock-Clover CM, et al. Effect of recombinant growth hormone and chromium picolinate on cytokine production and growth performance in swine. Pathobiology 1995; 63:283-287.
132. Evock-Clover CM, Polansky MM, Anderson RA, et al. Dietary chromium supplementation with or without somatotropin treatment alters serum hormones and metabolites in growing pigs without affecting growth performance. J Nutr 1993; 123:1504-1512.
133. Bunting LD, Fernandez JM, Thompson DL Jr., et al. Influence of chromium picolinate on glucose usage and metabolic criteria in growing Holstein calves. J Anim Sci 1994; 72:1591-1599.
134. Hasten DL, Rome EP, Franks BD, et al. Effects of chromium picolinate on beginning weight training students. Int J Sport Nutr 1992; 2:343-350.
135. Grant KE, Chandler RM, Castle AL, et al. Chromium and exercise training: effect on obese women. Med Sci Sports Exerc 1997; 29:992-998.
136. Clancy SP, Clarkson PM, DeCheke ME, et al. Effects of chromium picolinate supplementation on body composition, strength, and urinary chromium loss in football players. Int J Sport Nutr 1994; 4:142-153.
137. Trent LK, Thieding-Cancel D. Effects of chromium picolinate on body composition. J Sports Med Phys Fitness 1995; 35:273-280.
138. Lukaski HC, Bolonchuk WW, Siders WA, et al. Chromium supplementation and resistance training: effects on body composition, strength, and trace element status of men. Am J Clin Nutr 1996; 63:954-965.
139. Bahadori B, Wallner S, Schneider H, et al. Effect of chromium yeast and chromium picolinate on body composition of obese, nondiabetic patients during and after a formula diet. Acta Med Austriaca 1997; 24:185-187.
140. Pasman WJ, Westerterp-Plantenga MS, Saris WH. The effectiveness of long-term supplementation of carbohydrate, chromium, fibre and caffeine on weight maintenance. Int J Obes Relat Metab Disord 1997; 21:1143-1151.
141. Walker LS, Bemben MG, Bemben DA, et al. Chromium picolinate effects on body composition and muscular performance in wrestlers. Med Sci Sports Exerc 1998; 30:1730-1737.
142. Campbell WW, Joseph LJ, Davey SL, et al. Effects of resistance training and chromium picolinate on body composition and skeletal muscle in older men. J Appl Physiol 1999; 86:29-39.
143. Volpe SL, Huang HW, Larpadisorn K, et al. Effect of chromium supplementation and exercise on body composition, resting metabolic rate and selected biochemical parameters in moderately obese women following an exercise program. J Am Coll Nutr 2001; 20:293-306.
144. Press RI, Geller J, Evans GW. The effect of chromium picolinate on serum cholesterol and apolipoprotein fractions in human subjects. West J Med 1990; 152:41-45.
145. Lee NA, Reasner CA. Beneficial effect of chromium supplementation on serum triglyceride levels in NIDDM. Diabetes Care 1994; 17:1449-1452.
146. Preuss HG, Grojec PL, Lieberman S, et al. Effects of different chromium compounds on blood pressure and lipid peroxidation in spontaneously hypertensive rats. Clin Nephrol 1997; 47:325-330.
147. Anderson RA. Nutritional factors influencing the glucose/insulin system: chromium. J Am Coll Nutr 1997; 16:404-410.
148. Anderson RA, Cheng N, Bryden NA, et al. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 1997; 46:1786-1791.
149. Evans GW, Bowman TD. Chromium picolinate increases membrane fluidity and rate of insulin internalization. J Inorg Biochem 1992; 46:243-250.
150. Stearns DM, Wise JP Sr., Patierno SR, et al. Chromium (III) picolinate produces chromosome damage in Chinese hamster ovary cells. FASEB J 1995; 9:1643-1648.
151. Stearns DM, Belbruno JJ, Wetterhahn KE. A prediction of chromium(III) accumulation in humans from chromium dietary supplements. FASEB J 1995; 9:1650-1657.
152. Anderson RA, Bryden NA, Polansky MM. Lack of toxicity of chromium chloride and chromium picolinate in rats. J Am Coll Nutr 1997; 16:273-279.
153. Vincent JB. The biochemistry of chromium. J Nutr 2000; 130:715-718.
154. McCarron DA, Morris CD, Henry HJ, et al. Blood pressure and nutrient intake in the United States. Science 1984; 224:1392-1398.
155. Zemel MB, Shi H, Greer B, et al. Regulation of adiposity by dietary calcium. FASEB J 2000; 14:1132-1138.
156. Zemel MB, Thompson W, Milstead A, et al. Calcium and dairy acceleration of weight and fat loss during energy restriction in obese adults. Obes Res 2004; 12:582-590.
157. Zemel MB, Richards J, Milstead A, et al. Effects of calcium and dairy on body composition and weight loss in African-American adults. Obes Res 2005; 13:1218-1225.
158. Zemel MB, Richards J, Mathis S, et al. Dairy augmentation of total and central fat loss in obese subjects. Int J Obes (Lond) 2005; 29:391-397.
159. Thompson WG, Rostad Holdman N, Janzow DJ, et al. Effect of energy-reduced diets high in dairy products and fiber on weight loss in obese adults. Obes Res 2005; 13:1344-1353.
160. Lappe JM, Rafferty KA, Davies KM, et al. Girls on a high-calcium diet gain weight at the same rate as girls on a normal diet: a pilot study. J Am Diet Assoc 2004; 104:1361-1367.
161. Lin YC, Lyle RM, McCabe LD, et al. Dairy calcium is related to changes in body composition during a two-year exercise intervention in young women. J Am Coll Nutr 2000; 19:754-760.
162. Davies KM, Heaney RP, Recker RR, et al. Calcium intake and body weight. J Clin Endocrinol Metab 2000; 85:4635-4638.
163. Shapses SA, Heshka S, Heymsfield SB. Effect of calcium supplementation on weight and fat loss in women. J Clin Endocrinol Metab 2004; 89:632-637.
164. Shapses SA, Von Thun NL, Heymsfield SB, et al. Bone turnover and density in obese premenopausal women during moderate weight loss and calcium supplementation. J Bone Miner Res 2001; 16:1329-1336.
165. Barr SI. Increased dairy product or calcium intake: is body weight or composition affected in humans? J Nutr 2003; 133:245S-248S.
166. Bowen J, Noakes M, Clifton PM. Effect of calcium and dairy foods in high protein, energy-restricted diets on weight loss and metabolic parameters in overweight adults. Int J Obes (Lond) 2005; 29:957-965.
167. Nissen S, Sharp R, Ray M, et al. Effect of leucine metabolite beta-hydroxy-beta-methylbutyrate on muscle metabolism during resistance-exercise training. J Appl Physiol 1996; 81:2095-2104.
168. Kreider RB, Ferreira M, Wilson M, et al. Effects of calcium beta-hydroxy-beta-methylbutyrate (HMB) supplementation during resistance-training on markers of catabolism, body composition and strength. Int J Sports Med 1999; 20:503-509.
169. Lamboley CR, Royer D, Dionne IJ. Effects of betahydroxy- beta-methylbutyrate on aerobic-performance components and body composition in college students. Int J Sport Nutr Exerc Metab 2007; 17:56-69.
170. Ransone J, Neighbors K, Lefavi R, et al. The effect of beta-hydroxy-beta-methylbutyrate on muscular strength and body composition in collegiate football players. J Strength Cond Res 2003; 17:34-39.
171. Vukovich MD, Stubbs NB, Bohlken RM. Body composition in 70-year-old adults responds to dietary betahydroxy- beta-methylbutyrate similarly to that of young adults. J Nutr 2001; 131:2049-2052.
172. Nissen S, Sharp RL, Panton L, et al. Beta-hydroxy-betamethylbutyrate (HMB) supplementation in humans is safe and may decrease cardiovascular risk factors. J Nutr 2000; 130:1937-1945.
173. Ronsard N. Cellulite: Those Lumps, Bumps, and Bulges You Couldn’t Lose Before. New York: Beauty and Health Publishing Co., 1973.
174. Arner P. Adrenergic receptor function in fat cells. Am J Clin Nutr 1992; 55:228S-236S.
175. Arner P, Hellstrom L, Wahrenberg H, et al. Betaadrenoceptor expression in human fat cells from different regions. J Clin Invest 1990; 86:1595-1600.
176. Lafontan M, Berlan M. Fat cell adrenergic receptors and the control of white and brown fat cell function. J Lipid Res 1993; 34:1057-1091.
177. Presta E, Leibel RL, Hirsch J. Regional changes in adrenergic receptor status during hypocaloric intake do not predict changes in adipocyte size or body shape. Metabolism 1990; 39:307-315.
178. Vernon RG. Effects of diet on lipolysis and its regulation. Proc Nutr Soc 1992; 51:397-408.
179. Greenway FL, Bray GA. Regional fat loss from the thigh in obese women after adrenergic modulation. Clin Ther 1987; 9:663-669.
180. Greenway FL, Bray GA, Heber D. Topical fat reduction. Obes Res 1995; 3(suppl 4):561S-568S.
181. Collis N, Elliot LA, Sharpe C, et al. Cellulite treatment: a myth or reality: a prospective randomized, controlled trial of two therapies, endermologie and aminophylline cream. Plast Reconstr Surg 1999; 104:1110-1114.
182. Richardson TP, Murphy WL, Mooney DJ. Selective adipose tissue ablation by localized, sustained drug delivery. Plast Reconstr Surg 2003; 112:162-170.
183. Neira R, Arroyave J, Ramirez H, et al. Fat liquefaction:effect of low-level laser energy on adipose tissue. Plast Reconstr Surg 2002; 110:912-922.
184. Lis-Balchin M. Parallel placebo-controlled clinical study of a mixture of herbs sold as a remedy for cellulite. Phytother Res 1999; 13:627-629.
185. Caruso MK, Pekarovic S, Raum WJ, et al. Topical fat reduction from the waist. Diabetes Obes Metab 2007; 9:300-303.
186. Mellinkoff S. Digestive system. Annu Rev Physiol 1957; 19:175-204.
187. Fernstrom JD. Role of precursor availability in control of monoamine biosynthesis in brain. Physiol Rev 1983; 63:484-546.
188. Wurtman RJ, Wurtman JJ. Carbohydrate craving, obesity and brain serotonin. Appetite 1986; 7(suppl):99-103.
189. Blundell JE, LeshemMB. The effect of 5-hydroxytryptophan on food intake and on the anorexic action of amphetamine and fenfluramine. J Pharm Pharmacol 1975; 27:31-37.
190. Birdsall TC. 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Altern Med Rev 1998; 3:271-280.
191. Weekley LB, Maher RW, Kimbrough TD. Alterations of tryptophan metabolism in a rat strain (Osborne-Mendel) predisposed to obesity. Comp Biochem Physiol A 1982; 72:747-752.
192. Ceci F, Cangiano C, Cairella M, et al. The effects of oral 5-hydroxytryptophan administration on feeding behavior in obese adult female subjects. J Neural Transm 1989; 76:109-117.
193. Cangiano C, Ceci F, Cascino A, et al. Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan. Am J Clin Nutr 1992; 56:863-867.
194. Growdon JH, Melamed E, Logue M, et al. Effects of oral L-tyrosine administration on CSF tyrosine and homovanillic acid levels in patients with Parkinson’s disease. Life Sci 1982; 30:827-832.
195. Avraham Y, Bonne O, Berry EM. Behavioral and neurochemical alterations caused by diet restriction: the effect of tyrosine administration in mice. Brain Res 1996; 732:133-144.
196. Hull KM, Maher TJ. L-tyrosine potentiates the anorexia induced by mixed-acting sympathomimetic drugs in hyperphagic rats. J Pharmacol Exp Ther 1990; 255:403-409.
197. Hull KM, Maher TJ. L-tyrosine fails to potentiate several peripheral actions of the sympathomimetics. Pharmacol Biochem Behav 1991; 39:755-759.
198. Hull KM, Maher TJ. Effects of L-tyrosine on mixedacting sympathomimetic-induced pressor actions. Pharmacol Biochem Behav 1992; 43:1047-1052.
199. Orentreich N, Matias JR., DeFelice A, et al. Low methionine ingestion by rats extends life span. J Nutr 1993; 123:269-274.
200. Epner DE, Morrow S, Wilcox M, et al. Nutrient intake and nutritional indexes in adults with metastatic cancer on a phase I clinical trial of dietary methionine restriction. Nutr Cancer 2002; 42:158-166.
201. Becker E, Jakober B, Luft D, al. Clinical and biochemical evaluations of the alga spirulina with regard to its application in the treatment of obesity. A double-blind crossover study. Nutr Rep Int 1986; 33:565-574.
202. Van Itallie TB. Dietary fiber and obesity. Am J Clin Nutr 1978; 31:S43-S52.
203. Krotkiewski M. Effect of guar gum on body-weight, hunger ratings and metabolism in obese subjects. Br J Nutr 1984; 52:97-105.
204. Kovacs EM, Westerterp-Plantenga MS, Saris WH, et al. The effect of addition of modified guar gum to a lowenergy semisolid meal on appetite and body weight loss. Int J Obes Relat Metab Disord 2001; 25:307-315.
205. Walsh DE, Yaghoubian V, Behforooz A. Effect of glucomannan on obese patients: a clinical study. Int J Obes 1984; 8:289-293.
206. Cairella M, Marchini G. Evaluation of the action of glucomannan on metabolic parameters and on the sensation of satiation in overweight and obese patients. Clin Ter 1995; 146:269-274.
207. Hylander B, Rossner S. Effects of dietary fiber intake before meals on weight loss and hunger in a weightreducing club. Acta Med Scand 1983; 213:217-220.
208. Porikos K, Hagamen S. Is fiber satiating? Effects of a high fiber preload on subsequent food intake of normal-weight and obese young men. Appetite 1986; 7:153-162.
209. Witkowska A, Borawska MH. The role of dietary fiber and its preparations in the protection and treatment of overweight. Pol Merkur Lekarski 1999; 6:224-226.
210. Pasman WJ, Saris WH, Wauters MA, et al. Effect of one week of fibre supplementation on hunger and satiety ratings and energy intake. Appetite 1997; 29:77-87.
211. Baron JA, Schori A, Crow B, et al. A randomized controlled trial of low carbohydrate and low fat/high fiber diets for weight loss. Am J Public Health 1986; 76:1293-1296.
212. Rigaud D, Ryttig KR, Angel LA, et al. Overweight treated with energy restriction and a dietary fibre supplement: a 6-month randomized, double-blind, placebo-controlled trial. Int J Obes 1990; 14:763-769.
213. Solum TT, Ryttig KR, Solum E, et al. The influence of a high-fibre diet on body weight, serum lipids and blood pressure in slightly overweight persons. A randomized, double-blind, placebo-controlled investigation with diet and fibre tablets (DumoVital). Int J Obes 1987; 11 (suppl 1):67-71.
214. Rossner S, von Zweigbergk D, Ohlin A, et al. Weight reduction with dietary fibre supplements. Results of two double-blind randomized studies. Acta Med Scand 1987; 222:83-88.
215. Birketvedt GS, Aaseth J, Florholmen JR, et al. Long-term effect of fibre supplement and reduced energy intake on body weight and blood lipids in overweight subjects. Acta Medica (Hradec Kralove) 2000; 43:129-132.
216. Lee YP, Mori TA, Sipsas S, et al. Lupin-enriched bread increases satiety and reduces energy intake acutely. Am J Clin Nutr 2006; 84:975-980.
217. Lee KW, Song KE, Lee HS, et al. The effects of Goami No. 2 rice, a natural fiber-rich rice, on body weight and lipid metabolism. Obesity (Silver Spring) 2006; 14:423-430.
218. Cani PD, Joly E, Horsmans Y, et al. Oligofructose promotes satiety in healthy human: a pilot study. Eur J Clin Nutr 2006; 60:567-572.
219. Thomson CA, Rock CL, Giuliano AR, et al. Longitudinal changes in body weight and body composition among women previously treated for breast cancer consuming a high-vegetable, fruit and fiber, low-fat diet. Eur J Nutr 2005; 44:18-25.
220. Maeda H, Yamamoto R, Hirao K, et al. Effects of agar (kanten) diet on obese patients with impaired glucose tolerance and type 2 diabetes. Diabetes Obes Metab 2005; 7:40-46.
221. Birketvedt GS, Shimshi M, Erling T, et al. Experiences with three different fiber supplements in weight reduction. Med Sci Monit 2005; 11:PI5-PI8.
222. Gropper SS, Acosta PB. The therapeutic effect of fiber in treating obesity. J Am Coll Nutr 1987; 6:533-535.
223. Ryttig KR, Tellnes G, Haegh L, et al. A dietary fibre supplement and weight maintenance after weight reduction:a randomized, double-blind, placebo-controlled longterm trial. Int J Obes 1989; 13:165-171.
224. Quaade F, Vrist E, Astrup A. Dietary fiber added to a very-low caloric diet reduces hunger and alleviates constipation. Ugeskr Laeger 1990; 152:95-98.
225. Pasman WJ, Westerterp-Plantenga MS, Muls E, et al. The effectiveness of long-term fibre supplementation on weight maintenance in weight-reduced women. Int J Obes Relat Metab Disord 1997; 21:548-555.
226. Miller WC, Niederpruem MG, Wallace JP, et al. Dietary fat, sugar, and fiber predict body fat content. J Am Diet Assoc 1994; 94:612-615.
227. Alfieri MA, Pomerleau J, Grace DM, et al. Fiber intake of normal weight, moderately obese and severely obese subjects. Obes Res 1995; 3:541-547.
228. Han LK, Kimura Y, Okuda H. Reduction in fat storage during chitin-chitosan treatment in mice fed a high-fat diet. Int J Obes Relat Metab Disord 1999; 23:174-179.
229. Wuolijoki E, Hirvela T, Ylitalo P. Decrease in serum LDL cholesterol with microcrystalline chitosan. Methods Find Exp Clin Pharmacol 1999; 21:357-361.
230. Pittler MH, Abbot NC, Harkness EF, et al. Randomized, double-blind trial of chitosan for body weight reduction. Eur J Clin Nutr 1999; 53:379-381.
231. Guerciolini R, Radu-Radulescu L, Boldrin M, et al. Comparative evaluation of fecal fat excretion induced by orlistat and chitosan. Obes Res 2001; 9:364-367.
232. Kaats GR, Michalek JE, Preuss HG. Evaluating efficacy of a chitosan product using a double-blinded, placebocontrolled protocol. J Am Coll Nutr 2006; 25:389-394.
233. Mhurchu CN, Poppitt SD, McGill AT, et al. The effect of the dietary supplement, chitosan, on body weight: a randomised controlled trial in 250 overweight and obese adults. Int J Obes Relat Metab Disord 2004; 28:1149-1156.
234. Rodgers S, Burnet R, Goss A, Phillips P, et al. Jaw wiring in treatment of obesity. Lancet 1977; 1:1221-1222.
235. Kark AE, Burke M. Gastric reduction for morbid obesity:technique and indications. Br J Surg 1979; 66:756-761.
236. Ross MW, Kalucy RS, Morton JE. Locus of control in obesity: predictors of success in a jaw-wiring programme. Br J Med Psychol 1983; 56(pt 1):49-56.
237. Ross MW, Goss AN, Kalucy RS. The relationship of panic-fear to anxiety and tension in jaw wiring for obesity. Br J Med Psychol 1984; 57(pt 1):67-69.
238. Garrow JS, Gardiner GT. Maintenance of weight loss in obese patients after jaw wiring. Br Med J (Clin Res Ed) 1981; 282:858-860.
239. Garrow JS, Webster JD, Pearson M, et al. Inpatient- outpatient randomized comparison of Cambridge diet versus milk diet in 17 obese women over 24 weeks. Int J Obes 1989; 13:521-529.
240. Pacy PJ, Webster JD, Pearson M. A cross-sectional cost/benefit audit in a hospital obesity clinic. Hum Nutr Appl Nutr 1987; 41:38-46.
241. Ramsey-Stewart G, Martin L. Jaw wiring in the treatment of morbid obesity. Aust N Z J Surg 1985; 55:163-167.
242. Simpson GK, Farquhar DL, Carr P, et al. Intermittent protein-sparing fasting with abdominal belting. Int J Obes 1986; 10:247-254.
243. Garrow JS. Morbid obesity: medical or surgical treatment? The case for medical treatment. Int J Obes 1987; 11(suppl 3):1-4.
244. Garrow JS. Treatment of morbid obesity by nonsurgical means: diet, drugs, behavior modification, exercise. Gastroenterol Clin North Am 1987; 16:443-449.
245. Garrow JS. Is it possible to prevent obesity? Infusionstherapie 1990; 17:28-31.
246. Garrow JS. The management of obesity. Another view. Int J Obes Relat Metab Disord 1992; 16(suppl 2):S59-S63.
247. Kirsch I, Montgomery G, Sapirstein G. Hypnosis as an adjunct to cognitive-behavioral psychotherapy: a metaanalysis. J Consult Clin Psychol 1995; 63:214-220.
248. Kirsch I. Hypnotic enhancement of cognitive-behavioral weight loss treatments: another meta-reanalysis. J Consult Clin Psychol 1996; 64:517-519.
249. Allison DB, Faith MS. Hypnosis as an adjunct to cognitivebehavioral psychotherapy for obesity: a meta-analytic reappraisal. J Consult Clin Psychol 1996; 64:513-516.
250. Johnson DL, Karkut RT. Participation in multicomponent hypnosis treatment programs for women’s weight loss with and without overt aversion. Psychol Rep 1996; 79:659-668.
251. Johnson DL. Weight loss for women: studies of smokers and nonsmokers using hypnosis and multicomponent treatments with and without overt aversion. Psychol Rep 1997; 80:931-933.
252. Stradling J, Roberts D, Wilson A, et al. Controlled trial of hypnotherapy for weight loss in patients with obstructive sleep apnoea. Int J Obes Relat Metab Disord 1998; 22:278-281.
253. Haber CH, Nitkin R, Shenker IR. Adverse reactions to hypnotherapy in obese adolescents: a developmental viewpoint. Psychiatr Q 1979; 51:55-63.
254. Schoenberger NE. Research on hypnosis as an adjunct to cognitive-behavioral psychotherapy. Int J Clin Exp Hypn 2000; 48:154-169.
255. Cole AD, Bond NW. Olfactory aversion conditioning and overeating: a review and some data. Percept Mot Skills 1983; 57:667-678.
256. Wei Q, Liu Z. Effects of acupuncture on monoamine neurotransmitters in raphe nuclei in obese rats. J Tradit Chin Med 2003; 23:147-150.
257. Kwon YD, Lee JH, Lee MS. Increased temperature at acupuncture points induced by weight reduction in obese patients: a preliminary study. Int J Neurosci 2007; 117:591-595.
258. Mok MS, Parker LN, Voina S, et al. Treatment of obesity by acupuncture. Am J Clin Nutr 1976; 29:832-835.
259. Mazzoni R, Mannucci E, Rizzello SM, et al. Failure of acupuncture in the treatment of obesity: a pilot study. Eat Weight Disord 1999; 4:198-202.
260. Bahadori B, Wallner S, Wilders-Truschnig M, et al. Acupuncture as adjuvant therapy in obesity: effects on eating behavior and weight loss. Int J Obes Relat Metab Disord 2000; 24:S107.
261. Steiner R, Kupper N, Davis A. Obesity and appetite control:comparison of acupuncture therapies and behavior modification. Proceedings, International Forum on Family Medicine Education. Society of Teachers of Family Medicine, Kansas City, MO, 1983:313-326.
262. Cabioglu MT, Ergene N. Electroacupuncture therapy for weight loss reduces serum total cholesterol, triglycerides, and LDL cholesterol levels in obese women. Am J Chin Med 2005; 33:525-533.
263. Cabioglu MT, Ergene N. Changes in serum leptin and beta endorphin levels with weight loss by electroacupuncture and diet restriction in obesity treatment. Am J Chin Med 2006; 34:1-11.
264. Hsu CH, Hwang KC, Chao CL, et al. Effects of electroacupuncture in reducing weight and waist circumference in obese women: a randomized crossover trial. Int J Obes (Lond) 2005; 29:1379-1384.
265. Richards D, Marley J. Stimulation of auricular acupuncture points in weight loss. Aust Fam Physician 1998; 27(suppl 2):S73-S77.
266. Allison DB, Kreibich K, Heshka S, et al. A randomised placebo-controlled clinical trial of an acupressure device for weight loss. Int J Obes Relat Metab Disord 1995; 19:653-658.
267. Pittler MH, Ernst E. Complementary therapies for reducing body weight: a systematic review. Int J Obes (Lond) 2005; 29:1030-1038.
268. Schmidt JM, Ostermayr B. Does a homeopathic ultramolecular dilution of Thyroidinum 30cH affect the rate of body weight reduction in fasting patients? A randomised placebo-controlled double-blind clinical trial. Homeopathy 2002; 91:197-206.
269. Boozer CN, Nasser JA, Heymsfield SB, et al. An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial. Int J Obes Relat Metab Disord 2001; 25:316-324.
270. Coffey CS, Steiner D, Baker BA, et al. A randomized double-blind placebo-controlled clinical trial of a product containing ephedrine, caffeine, and other ingredients from herbal sources for treatment of overweight and obesity in the absence of lifestyle treatment. Int J Obes Relat Metab Disord 2004; 28:1411-1419.
271. Hackman RM, Havel PJ, Schwartz HJ, et al. Multinutrient supplement containing ephedra and caffeine causes weight loss and improves metabolic risk factors in obese women:a randomized controlled trial. Int J Obes (Lond) 2006; 30:1545-1556.